The acquisition of Colorado-based biotech Array BioPharma in July 2019 sets the stage for Pfizer to create a potentially industry-leading franchise for colorectal cancer alongside the company’s leadership in breast and prostate cancers.

Array became known for its scientific acumen and nimble culture. This acquisition brought exceptional talent to Pfizer, as well as an impressive and broad pipeline of targeted small-molecule medicines being investigated to treat cancer and other diseases of high unmet need. The portfolio includes the approved combined use of Braftovi^® (encorafenib) and Mektovi^® (binimetinib) for the treatment of BRAF-mutant metastatic melanoma. The treatments have significant potential for growth and expansion into additional areas of unmet need, evident by the more than 30 clinical trials investigating combinations for a wide variety of tumor types, including BRAF-mutant metastatic colorectal cancer. BRAF mutations are estimated to occur in up to 15% of cases of colorectal cancer, one of the leading causes of cancer-related death worldwide.

The Boulder, Colorado site adds a new and highly productive hub to Pfizer’s research network. Colleagues in Boulder will continue working to translate advanced science and technologies into breakthrough medicines. The Boulder research unit will further fuel the first-in-class science that sets Pfizer’s leadership apart – working to discover and advance small molecules to impact and extend the lives of patients in critical need of transformational therapies.